Lymphoma (includes NHL, HL, CNS Lymphoma)

Copanlisib Tested in Relapsed/ Refractory Indolent Lymphoma

(MedPage Today) Oct 12, 2017 - The kinase inhibitor copanlisib (Aliqopa), recently approved as third-line therapy for relapsed follicular lymphoma, appeared safe and effective in patients with relapsed or refractory indolent lymphoma, according to a phase II study.

read article (free registration required)

Remetinostat Phase II Data Demonstrate Efficacy On Skin Lesions, Reduction Of Itching And High Tolerability In Patients With Early-Stage MF-Type CTCL

(Medivir) Oct 13, 2017 - Medivir AB today announces that phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions.

read corporate press release

miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force...

(Business Insider) Oct 13, 2017 - miRagen Therapeutics, Inc. announced today new interim results from its ongoing Phase 1 clinical trial evaluating the safety, efficacy and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

read article

Immunotherapy Treatments For Cancer Gain Momentum

(Wall Street Journal) Oct 12, 2017 - In recent case, woman with metastatic breast cancer is cancer-free after infusion of immune cells at National Cancer Institute.

read article (paid subscription required)

Cancer Researchers Learn More About Toxic Side Effects Of New Treatments

(Washington Post/To Your Health) Oct 12 2017 - Scientists at major cancer centers detail the most common side effects of CAR T-cell immunotherapy and ways to spot and reduce them.

read article (free registration required)

U of T Startup Janpix Receives $22 Million In Funding To Advance Cancer Therapies

(U of T News) Oct 11, 2017 - STATs have been identified in numerous human cancers, including breast, blood and brain tumours. A University of Toronto researcher is developing ways to inhibit two STAT proteins, STAT3 and STAT5.

read press release

Researchers Identify Genetic Drivers of Most Common Form of Lymphoma

(Duke Health) Oct 5, 2017 - More than 150 genetic mutations play a role in diffuse large B cell lymphoma.

read press release

Obinutuzumab vs Rituximab in FL: 'Too Close to Call’

(Medscape Medical News) Oct 4, 2017 - Obinutuzumab for induction and maintenance provides significantly higher PFS than rituximab, the current standard of care for follicular lymphoma (FL). But an editorial cautions it's too soon to tell.

read article (free registration required)

Inova Schar Cancer Institute Recruiting Patients For ASCO's Groundbreaking TAPUR Clinical Trial

(Inova) Oct 5, 2017 - Inova Schar Cancer Institute announced today it is recruiting patients for the American Society of Clinical Oncology's (ASCO) first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

read press release

Adding Drug to Standard Care May Prolong Lymphoma Survival

(U.S. News & World Report/HealthDay News) Sept 27, 2017 - Long-term treatment with the drug rituximab (Rituxan) may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds.

read article

Tattoos Can Cause Infections 15 Years Later, Warn Doctors

(The Telegraph [UK]) Oct 2, 2017 - Tattoos can cause infections 15 years after they were drawn, doctors have warned after a woman was admitted to hospital suffering enlarged lymph nodes.

read article

Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma

(Seattle Genetics) Oct 2, 2017 - Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.

read corporate press release

NICE Knocks-Back Janssen's Imbruvica In Mantle Cell Lymphoma

(PharmaTimes [UK]) Sept 28, 2017 - Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib).

read article

Nation’s Experts in Hematologic Malignancies to Discuss Latest Treatment Advances and Examine Patient Cases during NCCN 12th Annual Congress

(NCCN) Sept 22, 2017 - NCCN 12th Annual Congress: Hematologic Malignancies™ will be held October 6 – 7, 2017 in San Francisco, California, and features a new Nursing Forum.

read press release

Roche Receives EU Approval Of Gazyvaro For People With Previously Untreated Advanced Follicular Lymphoma

(Roche) Sept 22, 2017 - Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma.

read corporate press release

Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma

(Medscape Medical News) Sept 18, 2017 - For patients with early-stage cutaneous lymphoma, skin-directed treatments, such as topical steroids and phototherapy, can slow or halt progression, but patients are also being treated with systemic therapies, according to the first-of-its kind research on this rare malignancy.

read article (free registration required)

NICE Rejects First-Line Use Of Roche’s Gazyvaro

(PharmaTimes [UK]) Sept 18, 2017 - The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro in patients with untreated advanced follicular lymphoma on the NHS in England and Wales.

read article

Autolus Announces Initiation of the AMELIA and ALEXANDER Studies for AUTO3: Phase I/II Studies in Paediatric ALL and DLBCL

(Autolus) Sept 18, 2017 - Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced initiation of both the AMELIA and ALEXANDER phase I/II studies of its novel, dual-targeting, AUTO3 Chimeric Antigen Receptor (CAR) T-cell therapy.

read corporate press release

FDA Adds Two Roche Studies To Its Growing List Of Partial Clinical Holds In Wake Of Keytruda Deaths

(Endpoints News) Sept 15, 2017 - Alarmed that an imbalance in deaths among patients taking a combination of Keytruda with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint combos, the FDA has added two Tecentriq studies to its growing list of clinical trials placed on partial hold.

read article

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

(Yahoo! Finance [UK]) Sept 18, 2017 - Karus Therapeutics, a leader in the development of innovative, orally-active medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237.

read article
Next Page